NDC 55513-224

Riabni

Rituximab-arrx

Riabni is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amgen Inc. The primary component is Rituximab.

Product ID55513-224_84dead0f-5d99-4ac4-9416-37d3ebaaa776
NDC55513-224
Product TypeHuman Prescription Drug
Proprietary NameRiabni
Generic NameRituximab-arrx
Dosage FormInjection, Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2021-01-06
Marketing CategoryBLA /
Application NumberBLA761140
Labeler NameAmgen Inc
Substance NameRITUXIMAB
Active Ingredient Strength100 mg/10mL
Pharm ClassesCD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 55513-224-01

1 VIAL, SINGLE-DOSE in 1 CARTON (55513-224-01) > 10 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date2021-01-06
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Riabni" or generic name "Rituximab-arrx"

NDCBrand NameGeneric Name
55513-224Riabnirituximab-arrx
55513-326Riabnirituximab-arrx

Trademark Results [Riabni]

Mark Image

Registration | Serial
Company
Trademark
Application Date
RIABNI
RIABNI
88182290 not registered Live/Pending
Amgen Inc.
2018-11-05

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.